At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 512 enrolled
Drug / intervention
Drug: AC-170 0.24% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 0.24% Ophthalmic Solution Used Twice Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)
In Brief
A Phase 3 clinical trial evaluating Drug: AC-170 0.24% and AC-170 0% for Atopic Disease (Including Allergic Conjunctivitis). Completed, enrolled 512 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMay 2014
First PostedMay 2014
Primary CompletionOct 2014
TodayJul 2026
First PostedMay 7, 2014
Enrollment StartMay 1, 2014
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.2 years ago
Interventions
Drug: AC-170 0.24%drug
AC-170 0%drug